Last updated on November 2017

LixiLan-G EFC13794

Brief description of study

LixiLan-G EFC13794

Detailed Study Description

A 26-week open-label study assessing the efficacy and safety of the insulin glargine/lixisenatide fixed ratio combination in adults with Type 2 Diabetes inadequately controlled on GLP-1 receptor agonist and metformin ± pioglitazone.

Clinical Study Identifier: TX14904

Contact Investigators or Research Sites near you

Start Over

Denise Esparza

Diabetes Associates Medical Group / Clinical Research
Orange, CA USA